Personalized cancer vaccines pass first major clinical test

Elie Dolgin • July 12, 2023

Moderna, BioNTech and others hope that personalized cancer vaccines will soon live up to their potential — even as they work out the wrinkles for the best use of their platform technologies.

Researchers have long suspected that therapeutic vaccines customized to a patient’s cancer might help raise the immune system to fight off the disease. Phase II data from a randomized trial of Moderna’s personalized vaccine mRNA-4157 now provide evidence that these therapeutics can yield meaningful — if still preliminary — clinical benefit.


The findings, reported earlier this year, have revitalized the cancer vaccine community, inspiring companies to intensify efforts to stimulate the immune system to recognize tumour-specific mutations known as neoantigens or neoepitopes.


Continue reading at Nature Reviews Drug Discovery.

Tubes of blood, one looks like an hourglass but with a woman's head
By Elie Dolgin April 16, 2025
Circulating biomarkers are quickly becoming a crucial part of diagnosis and disease monitoring for physicians, researchers — and even some consumers.
Zebra wearing video camera-equipped collar
By Elie Dolgin February 13, 2025
Zebras and giraffes offer one another protection without food competition.